EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) announced the initiation of its pivotal Phase 3 program evaluating DURAVYU for diabetic macular edema ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE